New developments in the combination treatment of COPD: Focus on umeclidinium/vilanterol

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1201-1208

  Cazzola, Mario ^a   Segreti, Andrea ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

COPD; Dual bronchodilation; Muscarinic antagonist

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM PLUS INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL PLUS TIOTROPIUM; PLACEBO; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; VILANTEROL;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

COPD; DUAL BRONCHODILATION; MUSCARINIC ANTAGONIST;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FORCED EXPIRATORY VOLUME; HUMANS; MUSCARINIC ANTAGONISTS; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES;

EID: 84885231930     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S39449     Document Type: Article

References (41)

1. Qaseem A, Wilt TJ, Weinberger SE, et al; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
2. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2013. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed June 20, 2013.
3. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450-504.
4. Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther. 2013;26:218-228.
5. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD. 2009;6:404-415.
6. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21:101-108.
7. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199-209.
8. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc. 2005;2:272-281.
9. Cazzola M, Molimard M. The scientific rationale for combining long-acting f{hook}À2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257-267.
10. Cazzola M, Calzetta L, Matera MG. f{hook}À2-adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011;163:4-17.
11. Meurs H, Oenema TA, Kistemaker LE, Gosens R. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol. 2013;13:316-323.
12. Meurs H, Dekkers BG, Maarsingh H, Halayko AJ, Zaagsma J, Gosens R. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26:145-155.
13. Ahmedat AS, Warnken M, Juergens UR, Paul Pieper M, Racke K. f{hook}À2-adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in human lung fibroblasts. Eur J Pharmacol. 2012;691:218-224.
14. Profita M, Bonanno A, Montalbano AM, et al. f{hook}À2 long-acting and anticholinergic drugs control TGF-f{hook}À1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta. 2012;1822:1079-1089.
15. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
16. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci. 2011;32:495-506.
17. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs. 2012;21:1489-1501.
18. Cazzola M, Page CP, Rogliani P, Matera MG. f{hook}À2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187:690-696.
19. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14:775-781.
20. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345:260-270.
21. Tal-Singer R, Cahn A, Mehta R, et al. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol. 2013;701:40-48.
22. Cahn A, Tal-Singer R, Pouliquen IJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies. Clin Drug Investig. 2013;33:477-488.
23. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185:393-399.
24. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106: 970-979.
25. Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting f{hook}À2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344: 218-230.
26. Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting f{hook}À2-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013;41:89-100.
27. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26: 256-264.
28. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting f{hook}À2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142:119-127.
29. Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012;7:e50716.
30. Kelleher D, Tombs L, Crater G, Preece A, Brealey N, Mehta R. A placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Am J Respir Crit Care Med. 2013;187:A1487.
31. Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25:465-471.
32. Donohue JF, Maleki-Yazdi M, Kilbride S, Mehta R, Kalberg CJ, Church A. ride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013 Jul 2. [Epub ahead of print].
33. Celli BR, Crater G, Kilbride S, et al. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD. Am J Respir Crit Care Med. 2013;187:A2435.
34. Anzueto A, Decramer M, Kaelin T, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD. Am J Respir Crit Care Med. 2013;187:A4268.
35. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26:307-317.
36. Charlton SJ. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol. 2009;158:165-168.
37. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest. 2001;119:1347-1356.
38. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:371-384.
39. Wu K, Looby M, Pillai G, Pinault G, Drollman AF, Pascoe S. Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients. J Pharmacokinet Pharmacodyn. 2011;38:105-119.
40. Church A, Kalberg C, Shah P, Beerahee M, Donohue J. An analysis of the dose response of umeclidinium (GSK573719) administered once or twice daily in patients with COPD. Chest. 2012;142:672A.
41. Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B. Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med. 2012;106: 1110-1115.